

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 8-K

CHINA PHARMA HOLDINGS, INC.

Form 8-K

February 28, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 25, 2008

CHINA PHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-29523	73-1564807
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification Number)

2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China,
(Address of principal executive offices)

0086-898-66811730 (China)

(Registrant's telephone number, including area code)

Not applicable

(Former Name or Former Address if changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 8-K

Item 2.02 Results of Operations and Financial Condition.

On February 25, 2008, China Pharma Holdings, Inc., a Delaware corporation (the "Company") issued a press release announcing, among other things, (i) new purchase orders, totaling approximately \$5,600,000, from one of its main distributors, for its Pusen OK product, a generic version of Aleve-D, (ii) preliminary, unaudited, revenues for the Company of approximately \$33,000,000 for the fiscal year ending on December 31, 2007, and (iii) preliminary, unaudited, revenues of approximately \$4,100,000 for its Pusen OK product for the fiscal year ending on December 31, 2007.

The press release is furnished and attached hereto as Exhibit 99.1 and is incorporated by reference.

Section 8-Other Events

Item 8.01 Other Events.

The Information set forth above in "Item 2.02 - Results of Operations and Financial Condition" is incorporated herein by reference.

The press release is furnished and attached hereto as Exhibit 99.1 and is incorporated by reference.

Section 9-Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release dated February 25, 2008

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.

Date: February 28, 2008

CHINA PHARMA HOLDINGS, INC.,
a Delaware corporation

By: /s/ Zhilin Li

Title: Chief Executive Officer